Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00232661 · ClinicalTrials.gov registry record · Phase 3
PROACT - Pre-Operative Arimidex Compared To Tamoxifen
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 452
- Enrollment target
NCT00232661 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 452 participants.
The verdict
NCT00232661, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 452 participants
- Enrollment target
Study Summary
The purpose of this study is to compare tamoxifen, versus a newer treatment, ARIMIDEX, which we already know to be well tolerated. The main objectives of this research study are to see whether using these drugs will shrink down tumours before surgery and to see if any shrinkage in the tumour affects the extent of surgery that is required.
Interventions
- DRUG ARIMIDEX (anastrazole)
- DRUG NOLVADEX (tamoxifen)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 452 participants |
| Start Date | 2000-08 |
| Est. Completion | 2007-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00232661
The ClinicalTrials.gov registry entry for NCT00232661 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 452 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ARIMIDEX (anastrazole) is the first listed.
NCT00232661 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00232661 about?
NCT00232661 is a clinical study titled "PROACT - Pre-Operative Arimidex Compared To Tamoxifen". The purpose of this study is to compare tamoxifen, versus a newer treatment, ARIMIDEX, which we already know to be well tolerated. The main objectives of this research study are to see whether using these drugs will shrink down tumours before surgery and to see if any shrinkage in the tumour affects...
What is the current status of trial NCT00232661?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 452 participants. The study started on 2000-08. Estimated completion is 2007-12.
What interventions are being tested in trial NCT00232661?
The interventions under investigation include: ARIMIDEX (anastrazole) (DRUG), NOLVADEX (tamoxifen) (DRUG).
Who is sponsoring clinical trial NCT00232661?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.